Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06352632 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ACT-GLOBAL Adaptive Platform Trial for Stroke

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Interventions: Both deferoxamine mesylate and colchicine (Drug), Colchicine only (Drug), Conservative Blood Pressure Control (Other), Deferoxamine… to Both deferoxamine mesylate and colchicine (Drug), Colchicine only (Drug), Conservative Blood Pressure Control (Other), Deferoxamine… Study arms: 4 to 5v7 Show 1 more changeShow less
    • Study arms: 4 to 5
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of May 2024 to Sep 26, 2024 · Study sites: 0 to 2 · Primary and study completion dates: May 2034 to Sep 2034 · 3 morev6 Show 6 more changesShow less
    • Start date changed from estimate of May 2024 to Sep 26, 2024
    • Study sites: 0 to 2
    • Primary and study completion dates: May 2034 to Sep 2034
    • Interventions: Conservative Blood Pressure Control (Other), Intensive Blood Pressure Control (Other), Low-dose intravenous tenecteplase (Drug), Moderate… to Both deferoxamine mesylate and colchicine (Drug), Colchicine only (Drug), Conservative Blood Pressure Control (Other), Deferoxamine…
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study arms: 3 to 4
  3. Primary completion date: Apr 2024 to May 2034 Completion date: Apr 2034 to May 2034 · Start date: Apr 2024 to May 2024v5 Show 2 more changesShow less
    • Completion date: Apr 2034 to May 2034
    • Start date: Apr 2024 to May 2024
  4. Study title shortened, about 5 wordsv4 See this version in full on ClinicalTrials.gov ↗
  5. Study title expanded, about 6 wordsv3 See this version in full on ClinicalTrials.gov ↗
  6. Primary endpoint revised Secondary endpoints: details revised at 3 of 3 entries · Study title shortened, about 6 wordsv2 Show 2 more changesShow less
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study title shortened, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The George Institute
19 trials monitored
See 1 trial at risk
Stroke
3,289 trials monitored
See 141 trials at risk
Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.
Trial Details
NCT Number NCT06352632
Lead Sponsor The George Institute
Collaborators: University of Calgary, Berry Consultants
Conditions Stroke
Enrollment 20,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov